Kidney Cancer News and Research

RSS

Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.

Genomic Deletions Drive Development of Melanoma Drug Resistance

Melanoma is the deadliest form of skin cancer. With global incidence rates rising, new, more effective treatments are necessary to alleviate the health burden of the disease. Important advances in recent years include doctors using genetic tests to look for specific mutations they can target for more personalised, effective treatment.

15 Apr 2024

Researchers Develop Bio-Inspired Drug to Boost Efficacy of Cancer Immunotherapy

A new, bio-inspired drug restores the effectiveness of immune cells in fighting cancer, a team led by researchers at The University of Texas at Austin has found.

10 Oct 2023

Study shows link between a mitochondrial metabolite and activation of inflammatory response

A new study shows for the first time a connection between a mitochondrial metabolite and the activation of an inflammatory response.

9 Mar 2023

Genes can be used to better predict the likelihood of kidney cancer recurrence

A decade-long international study into kidney cancer has shown that doctors can predict the likelihood of a patient's disease returning by looking at DNA mutations in their tumors.

24 Feb 2023

Innovative cancer therapy options with new cell death mechanism

Researchers from The University of Texas MD Anderson Cancer Center have described a previously unrecognized type of cell death called disulfidptosis in a study that was published in Nature Cell Biology.

7 Feb 2023

Immune cell patterns can help predict kidney cancer patients' response to immunotherapy

Researchers at the Francis Crick Institute, The Royal Marsden NHS Foundation Trust and UCL have found immune cell patterns within tumors that can help predict if patients with kidney cancer will respond to immunotherapy.

29 Oct 2021

Targeted drug shows promise against brain metastases from kidney cancer

A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.

22 Oct 2021

Immunotherapy following kidney cancer surgery prolonged disease-free survival rates

Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.

4 Jun 2021

Innovative technique encourages cancer cells in the kidneys to self-destruct

An innovative new technique that encourages cancer cells in the kidneys to self-destruct could revolutionize the treatment of the disease, a new study in the journal Pharmaceutics reports.

From University of Surrey 15 Apr 2021

Cancer immunotherapy patients experience potentially life-threatening side effects

Many patients with cancer receive immune checkpoint inhibitors that strengthen their immune response against tumor cells. While the medications can be life-saving, they can also cause potentially life-threatening side effects in internal organs.

13 Apr 2021

Researchers upend the models of cancer metabolism

Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.

From Vanderbilt University 8 Apr 2021

Researchers identify how melanoma redirects the immune system in cancer immunotherapy

The evolution of the refined human immune system has turned into an effective defense system against several diseases, including cancer.

21 Oct 2020

Study may help develop new immunotherapies for different types of tumors

A team of researchers have plotted the genes that enable cancer cells to avoid being destroyed by the immune system.

From University of Toronto 25 Sep 2020

Combination treatment improves outcomes in advanced kidney cancer patients

An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer.

24 Sep 2020

In-depth study of kidney tumors reveals novel markers of response to immunotherapy

Treatments for kidney cancer have improved considerably over the past few decades. In 1988, when Memorial Sloan Kettering oncologist Robert Motzer started researching the disease, the average survival was less than one year.

9 Sep 2020

Greater gut microbial diversity in kidney cancer patients linked to better treatment outcomes

Physicians at City of Hope, working in collaboration with scientists at Translational Genomics Research Institute (TGen), have found that greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on Food and Drug Administration-approved immunotherapy regimens.

20 Aug 2020

Detecting rare circulating tumor cells

Metastasis - the development of tumor growth at a secondary site - is responsible for the majority of cancer-related deaths.

4 Aug 2020

Diagnosing Brain Tumors With A Blood Test

A highly sensitive blood test has been found to accurately diagnose and classify different types of brain tumors, resulting in more accurate diagnosis.

23 Jun 2020

New sampling method can more accurately detect genetic alterations in tumors

A wholistic tumor sampling method that more accurately detects genetic alterations in tumors, which are critical in allowing treatment to be personalized to each and every patient, has been developed by researchers from the Crick, Roche and The Royal Marsden NHS Foundation Trust and published in Cell Reports.

12 May 2020